Pharmaceuticals Search Engine [selected websites]

Friday, March 30, 2012

Bristol-Myers Squibb and MESO SCALE DISCOVERY : Agreement to Develop Diagnostic Assays for Alzheimer's Disease

Meso Scale Discovery msd
March 28, 2012  – Bristol-Myers Squibb Company (NYSE:BMY) and Meso Scale Discovery announced they have entered an agreement to develop diagnostic assays that will measure cerebrospinal fluid biomarkers for use in Alzheimer's disease research.

Under the terms of the agreement, the companies will develop these assays based on the Meso Scale Discovery® MULTI-ARRAY technology platform. Meso Scale Discovery will commercialize the assays for Alzheimer's disease research and drug development, and plans to release the assays in the second quarter of 2012. Terms of the agreement were not disclosed.

Bristol-Myers Squibb bms

"The collaboration with Meso Scale Discovery demonstrates Bristol-Myers Squibb's commitment to advancing the science of Alzheimer's disease research," said Jane Tiller, vice president, Global Clinical Research, Bristol-Myers Squibb. "These assays could provide the Alzheimer's disease research community with an important tool to help advance understanding of this complex and devastating disease and may lead to advances in the diagnosis and treatment of Alzheimer's disease."... Meso Scale Discovery's Press Release - Bristol-Myers Squibb's Press Releases -

Thursday, March 15, 2012

PhRMA : Collaborations Between Public and Private Sector Are Critical to Advance Alzheimer’s Research

The Pharmaceutical Research and Manufacturers of America PhRMA
February 7, 2012 — The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani responded to new efforts unveiled by the Administration to combat Alzheimer’s Disease:

“Alzheimer’s disease is one of America’s top health challenges. It ravages the minds of patients, seriously impacts entire families and currently costs the U.S. health care system $172 billion a year. According to the Alzheimer’s Association, an American will develop the disease every 33 seconds in 2050, costing the U.S. health care system $1.1 trillion. These costs are simply unsustainable.

“The outlook could change course, however, if a treatment were discovered that helps delay the onset of Alzheimer’s. Biopharmaceutical research companies, recognizing the great health and economic need to help delay or prevent the onset of Alzheimer’s, have invested heavily in this area and are currently researching and developing nearly 100 medicines to help address this public health priority.

“Discovering an Alzheimer’s treatment is by no means an easy task; and it can certainly benefit from collaborations between industry, academia and federal research institutions. In addition to their individual efforts to discover and develop novel treatments for Alzheimer’s, biopharmaceutical companies have partnered with each other and with academic and federal research institutions to help move forward the scientific understanding of this complex disease... PhRMA's Press Release -

Thursday, March 8, 2012

Pfizer : Diagnosis of Alzheimer's and What You Need to Know as a Caregiver



One in eight people over 65 have Alzheimer's disease, and many more have personal experience as a family member or caregiver to someone with the disease. On The Doctors, Dr. Freda Lewis-Hall and Dr. Travis Stork discuss signs of dementia and key steps to take if you suspect someone in your life may have Alzheimer's disease. [PfizerNews on YouTube]